2024
DOI: 10.3390/biomedicines12051117
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

David K. Lau,
Jack P. Collin,
John M. Mariadason

Abstract: Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst the leading causes of cancer-related mortality worldwide. Importantly, the ongoing molecular characterisation of GCs continues to uncover potentially actionable molecular targets. Among these, aberrant FGFR2-driven signalling, predominantly arising from FGFR2 amp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 118 publications
0
0
0
Order By: Relevance